Nuvectis Pharma (NVCT) Price & Analysis

Compare

113 Followers

NVCT Stock Chart & Stats

$8.26

-$0.26(-4.17%)

At close: Jan 08 4:00 PM EST

$8.26

-$0.26(-4.17%)

Day’s Range― - ―

52-Week Range$4.44 - $11.52

Previous CloseN/A

Volume31.37K

Average Volume (3M)89.54K

Market Cap

$199.28M

Enterprise Value$101.33M

Total Cash (Recent Filing)$35.44M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.60

Next Earnings

Mar 10, 2026

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding25,614,897

10 Day Avg. Volume111,748

30 Day Avg. Volume89,536

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)9.53

Price to Sales (P/S)0.00

P/FCF Ratio-7.56

Enterprise Value/Market Cap0.51

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-3.93

Forecast

1Y Price Target

$15.67

Price Target Upside89.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.06

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe initiation of the Phase 1b NXP900 + osimertinib combo cohort is an important step forward.

Financial StabilityThe cash balance should provide sufficient funding into 3Q27.

Market OpportunityNXP900 is positioned for resistance where current options fall short, leaving a clear opportunity for its use.

Bears Say

Financial Performance3Q25 financial results posted an EPS of ($0.44) compared to an estimate of ($0.26) and a consensus of ($0.25), indicating a larger than expected loss.

Previous FailuresPrior combo developments by other companies with Src inhibitors + anti-tumor therapies failed due to poor Src inhibition.

Nuvectis Pharma News

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in...

7d ago

NVCT

Nuvectis Pharma: Buy Rating Backed by NXP900’s Potential to Overcome EGFR/ALK Inhibitor Resistance in NSCLC

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Nuvectis Pharma and keeping the price target...

5d ago

NVCT

Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies

Nuvectis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

6d ago

NVCT

NXP900: A Promising New Standard in Post-TKI NSCLC Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma today and set a price target...

21d ago

NVCT

Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Nuvectis Pharma, with...

1M ago

NVCT

Nuvectis Pharma Reports Progress in Oncology Drug Development

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

NVCT

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on...

2M ago

NVCT

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on...

2M ago

NVCT

Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment

Nuvectis Pharma, Inc. (($NVCT)) announced an update on their ongoing clinical study. Nuvectis Pharma, Inc. is currently conducting...

2M ago

NVCT

Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target...

2M ago

NVCT

Nuvectis Pharma provides highlights from NXP900 poster presentations

Nuvectis Pharma (NVCT) provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC...

2M ago

NVCT

Nuvectis Pharma Appoints Juan Sanchez to Board

Nuvectis Pharma ( ($NVCT) ) has provided an update. On September 22, 2025, Nuvectis Pharma appointed Juan Sanchez,...

3M ago

NVCT

Nuvectis Pharma appoints Juan Sanchez to board of directors

Nuvectis Pharma (NVCT) announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is...

3M ago

NVCT

Nuvectis Pharma initiates NXP900 program

Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b program for NXP900. Published first on TheFly –...

4M ago

NVCT

NVCT FAQ

What was Nuvectis Pharma’s price range in the past 12 months?

Nuvectis Pharma lowest stock price was $4.44 and its highest was $11.52 in the past 12 months.

What is Nuvectis Pharma’s market cap?

Nuvectis Pharma’s market cap is $199.28M.

When is Nuvectis Pharma’s upcoming earnings report date?

Nuvectis Pharma’s upcoming earnings report date is Mar 10, 2026 which is in 76 days.

How were Nuvectis Pharma’s earnings last quarter?

Nuvectis Pharma released its earnings results on Nov 04, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.19.

Is Nuvectis Pharma overvalued?

According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvectis Pharma pay dividends?

Nuvectis Pharma does not currently pay dividends.

What is Nuvectis Pharma’s EPS estimate?

Nuvectis Pharma’s EPS estimate is -0.31.

How many shares outstanding does Nuvectis Pharma have?

Nuvectis Pharma has 25,614,897 shares outstanding.

What happened to Nuvectis Pharma’s price movement after its last earnings report?

Nuvectis Pharma reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -7.547%.

Which hedge fund is a major shareholder of Nuvectis Pharma?

Currently, no hedge funds are holding shares in NVCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nuvectis Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-158.88%

Trailing 12-Months

Asset Growth

105.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvectis Pharma

Nuvectis Pharma (NVCT) is a biopharmaceutical company that operates within the healthcare and biotechnology sectors. The company focuses on the development and commercialization of innovative therapeutics for the treatment of cancer. Nuvectis Pharma leverages advanced scientific research to create novel drugs aimed at addressing unmet medical needs in oncology.

Nuvectis Pharma (NVCT) Earnings & Revenues

Historic Earnings Reports

NVCT Stock 12 Month Forecast

Average Price Target

$15.67

▲(89.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.94,7.021538461538462,8.103076923076923,9.184615384615384,10.266153846153845,11.347692307692306,12.429230769230768,13.510769230769231,14.592307692307692,15.673846153846153,16.755384615384614,17.836923076923075,18.918461538461536,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.94,6.688461538461539,7.436923076923078,8.185384615384617,8.933846153846154,9.682307692307692,10.430769230769233,11.17923076923077,11.927692307692308,12.676153846153847,13.424615384615386,14.173076923076923,14.921538461538464,{"y":15.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.94,6.252307692307693,6.564615384615385,6.876923076923077,7.18923076923077,7.501538461538462,7.813846153846154,8.126153846153846,8.438461538461539,8.750769230769231,9.063076923076924,9.375384615384615,9.687692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.69,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >